Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study

被引:0
|
作者
Armentaro, Giuseppe [1 ]
D'Arrigo, Graziella [2 ]
Pastori, Daniele [3 ]
Crudo, Giulia [1 ]
Daidone, Mario [4 ]
Soraci, Luca [5 ]
Pastura, Carlo Alberto [1 ]
Divino, Marcello [1 ]
Pitino, Annalisa [6 ]
Gori, Mercedes [6 ]
Tripepi, Giovanni [2 ]
Imbalzano, Egidio [7 ]
Corsonello, Andrea [5 ]
Pignatelli, Pasquale [3 ]
Andreozzi, Francesco [1 ]
Tuttolomondo, Antonino [4 ]
Sciacqua, Angela [1 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy
[2] Inst Clin Physiol IFC CNR, Sect Reggio Calabria, Reggio Di Calabria, Italy
[3] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy
[4] Univ Palermo, Internal Med & Stroke Care Ward, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, Palermo, Italy
[5] IRCCS, Unit Geriatr Med, INRCA, Cosenza, Italy
[6] Inst Clin Physiol IFC CNR, Sect Rome, Rome, Italy
[7] Univ Messina, Dept Clin & Expt Med, Messina, Italy
关键词
atrial fibrillation; cognitive impairment; NOACs; older; VKAs; DEMENTIA; IMPAIRMENT; DECLINE;
D O I
10.1111/eci.14321
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atrial fibrillation is associated with several comorbidities, particularly cognitive impairment and dementia, especially in older patients. Non- vitamin K oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) were used to prevent thromboembolic events. However, data on the real benefit of these drugs on cognitive function decline remains controversial. In this study we evaluated the effect of NOACs compared to VKAs on the absolute and relative decline in cognitive function over time. Methods: Nine hundred and eighty- three older patients with nonvalvular AF were enrolled (76 +/- 6 years; 291 on VKAs and 692 on NOACs). The cognitive function was assessed with Mini Mental State examination (MMSE) score. The between- arms difference of cognitive evolution over time was investigated by Linear Mixed Models and group- based trajectory model analyses. Results: In the whole multicenter observational study, after a long follow- up of 7.2 +/- 3.4 years, the patients of the NOACs versus VKAs group had lowest absolute reduction of the MMSE score between baseline and follow- up (-0.3 +/- 0.03 vs.-1.7 +/- 0.1, p < 0.001). After stratification into five subgroups according to trajectories of MMSE score over time, the probability to belong to trajectories with lower decline in cognitive functions was higher in patients on NOACs than in those on VKAs (3.93-13.88 times). Conclusion: In older patients with atrial fibrillation, the use of NOACs was associated with a smaller decline of cognitive function over time compared to the VKAs, regardless that patients in the NOACs group were older and with a higher burden of comorbidities.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Giugliano, Robert P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A1 - A10
  • [2] Uptake of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation a prospective cohort study
    Zimny, Matylda
    Blum, Steffen
    Ammann, Peter
    Erne, Paul
    Moschovitis, Giorgio
    Di Valentino, Marcello
    Shah, Dipen
    Schlapfer, Jurg
    Vogt, Cyril
    Tabord, Alexandra
    Kuhne, Michael
    Sticherling, Christian
    Osswald, Stefan
    Conen, David
    SWISS MEDICAL WEEKLY, 2017, 147
  • [3] Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
    Komen, Joris J.
    Heerdink, Eibert R.
    Klungel, Olaf H.
    Mantel-Teeuwisse, Aukje K.
    Forslund, Tomas
    Wettermark, Bjorn
    Hjemdahl, Paul
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (F11) : F72 - F80
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [5] Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
    Liu, Shin-Huei
    Chao, Tze-Fan
    Chan, Yi-Hsin
    Liao, Jo-Nan
    Chen, Tzeng-Ji
    Lip, Gregory Y. H.
    Chen, Shih-Ann
    EUROPACE, 2023, 25 (05):
  • [6] Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
    Gabitova, Mariia A.
    Krupenin, Pavel M.
    Sokolova, Anastasiya A.
    Napalkov, Dmitry A.
    Fomin, Victor V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (06) : 802 - 805
  • [7] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [8] Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
    Undas, Anetta
    Drabik, Leszek
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (01) : 10 - 18
  • [9] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [10] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6